

Download Program (PDF)

Sunday, 21 October 2018

Satellites
08:45 - 12:00

Estrasburgo

SA02, New Pieces to the HIV-1 Vaccine Puzzle: Germline Targeting Strategies and Immunization Protocols to Elicit Anti-HIV-1 bNAbs

Hosted by: The Rockefeller University

It is becoming evident that the design of a vaccine that elicits broadly protective antibodies against HIV-1 will require a meticulous engineering process to generate suitable germline targeting strategies that activate bNAb precursors and subsequently support antibody maturation in germinal centers. Encouraging results were obtained in a bNAb knock-in mouse model in which PGT121-like antibodies were elicited by step-wise immunization. Despite multiple efforts, these results have not been fully reproduced in wild type (wt) animal models with a polyclonal B cell repertoire. One of the hurdles to overcome in wt animals is the activation of bNAb precursors that are present in low frequencies. Recent studies have shown that high-affinity immunogens are necessary to efficiently activate and expand low-frequency bNAb precursors. An additional barrier for vaccine design in a wt system is the polyclonal nature of the antibody response. It is believed that immunogen refinement is necessary in order to focus the antibody response towards neutralizing epitopes and avoid distracting responses to non-neutralizing epitopes that could frustrate bNAb maturation by competition in the germinal centers. In this session, we will present progress achieved in the design of strategies to specifically activate and increase the frequency of bNAb precursors, as well as the results of immunization experiments aiming to elicit anti-HIV-1 bNAbs in wt animal models.

- 8:45 am Eliciting broadly neutralizing responses to the exposed N- terminal residues of the fusion peptide - Peter Kwong
- 9:00 am Discussion
- 9:05 am Induction of glycan-reactive bNAb B cell lineages - Kevin Saunders
- 9:20 am Discussion
- 9:25 am Sequential immunization strategies to elicit bNAbs in animal models with a polyclonal B cell repertoire - Amelia Escolano
- 9:40 am Discussion
- 9:45 am Design of germline targeting immunogens to elicit antibodies targeting the CD4-binding site and V3-N332 epitopes on Env - Harry Gristick
- 10:00 am Discussion
- 10:05 am Dissecting neutralizing antibodies to guide rational HIV vaccine design - Marit van Gils
- 10:20 am Discussion
- 10:25 am Nanoparticle-display of native-like envelope trimers - Kwinten Sliepen
- 10:40 am Discussion
- 10:45 am Anti-idiotypic antibodies as a strategy to prime bNAb precursors - Andrew McGuire
- 11:00 am Discussion
- 11:05 pm Structural basis for germline VRC01 antibody recognition of a glycosylated HIV-1 envelope CD4-binding site - Marie Pancera
- 11:20 am Discussion
- 11:25 am HIV-1 MPER Germline Targeting - Torben Schiffner
- 11:40 am Discussion
- 11:45 am Sequential Immunization with Different Repaired and Stabilized HIV-1 Envelope Trimers Induces broad Tier2 neutralization in Rabbits - Johannes P.M. Langedijk
- 11:55 pm Discussion

Chairs:

Amelia Escolano (The Rockefeller University, United States)
Marit van Gils (Amsterdam AMC, University of Amsterdam, Netherlands)

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Satellites
09:00 - 17:00

Dresden & Stuttgart

SA01, Advocates' Pre-Conference Workshop

Hosted by: IRMA, AVAC and others

This full day pre-conference workshop will provide an overview of the field and amplify certain topics to contextualize the themes and issues that will be presented at HIVR4P; will connect research and advocacy priorities and explore common goals; and build the capacity of advocates and trial staff to better engage with emerging issues in the field. This workshop is especially designed for advocates, scholarship recipients, new investigators, first time attendees, community liaison officers at trials and other interested stakeholders to what HIVR4P.

Chairs:

Jim Pickett (AIDS Foundation of Chicago, United States)

Satellites
12:30 - 15:30

Estrasburgo

SA03, Progress in Inducing HIV Broad Neutralizing Antibodies

Hosted by: The Scripps Research Institute and Duke University

This session will explore the progress made in inducing HIV broad neutralizing antibodies.

12:30 pm	Overview of the bnAb Problem- Barton Haynes
12:40 pm	V2 apex as a target - Raiees Andrabi
12:55 pm	Discussion
1:00 pm	Polyclonal Ab response mapping by EM - Andrew Ward
1:15 pm	Discussion
1:20 pm	Mouse models of bnAb germ line targeting immunogens - Facundo Batista
1:35 pm	Discussion
1:40 pm	Host control of bnAbs - Todd Bradley
1:55 pm	Discussion
2:00 pm	Overcoming roadblocks of improbable mutations in bnAb B cell lineages - Kevin Wiehe
2:15 pm	Discussion
2:20 pm	The impact of antibody isotype on neutralization - Penny Moore
2:35 pm	Discussion
2:40pm	Structural Diversity of antibody recognition at the V3-glycan epitope - Priyamvada Acharya
2:55 pm	Discussion
3:00 pm	SHIV infected Rhesus macaques as a model for bnAb development - George Shaw
3:15 pm	Discussion
3:20 pm	BnAbs - The way forward- Dennis Burton

Chairs:

Dennis Burton (The Scripps Research Institute, United States)
Barton Haynes (Duke University, United States)

Download Program (PDF)

Satellites
12:30 - 14:30

Marsella

SA06, Social Sciences in Vaccine Trials: A Booster to Recruit Volunteers

The recruitment of healthy, HIV-seronegative patients to HIV preventive vaccine trials has fluctuated since the early days of their implementation. There are numerous reasons for this, including the normalization of the epidemic, the displacement of HIV community action towards other causes, the transformation of disease management, and the lack of direct benefits. Vaccination is being increasingly rejected. At a time when scientific advances offer hope for the development of preventive HIV vaccine strategies, the recruitment of volunteers to future clinical trials may well become a stumbling block. This symposium aims to highlight the contribution that social science research has made to this complex process by both addressing the particular nature of HIV infection and placing the topic in a more global context of recruitment to preventive vaccine trials.

```
<table border="0" cellspacing="0" cellpadding="0" width="631">
<tbody>
<tr>
<td width="106">5 minutes </td>
<td width="525">Welcome </td>
</tr>
<tr>
<td></td>
<td>François Dabis, Director of the ANRS, France</td>
</tr>
<tr>
<td>5 minutes </td>
<td>Recruitment of healthy volunteers for HIV vaccine trials: a stumbling block?</td>
</tr>
<tr>
<td></td>
<td>Jean-Daniel Lelièvre, Vaccine Research Institute, France</td>
</tr>
<tr>
<td>15 minutes </td>
<td>Volunteers/Participants Recruitment/Enrolment in Africa</td>
</tr>
<tr>
<td></td>
<td>Morenike Folayan, Obafemi Awolowo University, Nigeria</td>
</tr>
<tr>
<td>15 minutes </td>
<td>US "Professionnal" healthy Participants Recruitment/Enrolment</td>
</tr>
<tr>
<td></td>
<td>Marci Cottingham, University of North Caroline, USA</td>
</tr>
<tr>
<td>15 minutes </td>
<td>Key Populations Enrolment</td>
</tr>
<tr>
<td></td>
<td>Peter Newman, University of Toronto, Canada</td>
</tr>
<tr>
<td>15 minutes </td>
<td>Participant Recruitment in an Outbreak Context: The Ebola vaccine trials in Sierra Leone</td>
</tr>
<tr>
<td></td>
<td>Luisa Enria, University of Bath, UK</td>
</tr>
<tr>
<td>40 minutes </td>
<td>General discussion and Round Table:</td>
</tr>
<tr>
<td></td>
<td>What Kind of Social Science Research to support Clinicians Issues?</td>
</tr>
```

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Satellites
14:00 - 17:00

Burdeos

SA05, Planning for Success: Next Steps for Dapivirine Ring

Hosted by: OPTIONS and IPM

Researchers, implementers, advocates, policy makers and dapivirine ring users will share research and experience to refine and coalesce on practical next steps for introduction.

Chairs:

Elizabeth Gardiner (AVAC, United States)

Nadia Sutton (Johnson & Johnson, Global Public Health, United States)

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Satellites
15:00 - 18:00

Marsella

SA07, Engagement of African MSM in HIV Prevention Research: Effective Recruitment and Retention

Hosted by: International AIDS Vaccine Initiative (IAVI) and the US Military HIV Research Program (MHRP)

The purpose of this meeting is to convene researchers and other stakeholders to discuss how African MSM can be successfully engaged in planned HIV biomedical prevention trials, discuss various recruitment and retention strategies from Africa and develop best practices and tools to inform future research in Africa and other regions.

<ol start="1">

□•Overview: HIV Prevalence, HIV Incidence, and Retention from Key African Studies of MSM – Joshua Kimani, University of Manitoba Kenya office

□•Plenary: Including African MSM in HIV biomedical prevention research – opportunities, challenges – Anatoli Kamali, IAVI

□•Lessons learned in recruitment and retention of African MSM

<ol start="1">

□•Frederick Otieno, Nyanza Reproductive Health Society

□•Elizabeth Wahome, KEMRI

□•Zahra Parker, Research Manager, U.S. Military HIV Research Program-Nigeria

□•Hannah Kibuuka, Research Physician, Makerere University Walter Reed Project

□•Victor Akelo, KEMRI/CDC Senior Research Officer, Kisumu, Kenya

□•Travis Sanchez, Emory University

<ol start="4">

□•Strategic community engagement

<ol start="1">

□•Sylvia Adebajo, Population Council, Nigeria

□•Jeffrey Walimbwa, ISHTAR, Kenya

<ol start="5">

□•Moderated Panel Q & A Discussion

□•Closing remarks – Merlin Robb, U.S. Military HIV Research Program

Chairs:

Kenneth H. Mayer (Fenway Health, United States)
Sylvia Adebajo (Population Council, Nigeria)

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Satellites
16:00 - 18:00

Estrasburgo

SA04, State of the Art of HIV bNAbs for Prevention of HIV Infection

Hosted by: HIV Vaccine Trials Network and HIV Prevention Trials Network

This session will cover current topics on the clinical development of broadly active neutralizing antibodies to HIV.

Chairs:

Larry Corey (Fred Hutchinson Cancer Research Center, United States)
Myron Cohen (University of North Carolina, United States)

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Monday, 22 October 2018

Satellites
08:30 - 11:30

Bristol

SA16, Current State of Play: PrEP Implementation Update and Challenges

Hosted by: ICAP at Columbia University, World Health Organization (WHO), AVAC, CHAI and HIV Prevention Trials Network (HPTN)

This session will provide participants with an update on where we are with PrEP and future products, current understanding of the different approaches to oral PrEP implementation in low- and middle-income countries, the challenges faced and solutions found in efforts to scale-up programs. Panel discussions will elicit the perspectives from key experts and include debate on current controversies when considering and prioritizing PrEP implementation.

Chairs:

Wafaa El-Sadr (Mailman School of Public Health, Columbia University, United States)
Rachel Baggaley (World Health Organization, Switzerland)

Satellites
08:30 - 11:30

Oxford

SA18, A Treasure Trove of Clinical Specimens and Data: Mining Research Opportunities with the HIV Vaccine Trials Network (HVTN)

Hosted by: HIV Vaccine Trials Network (HVTN)

The HVTN has conducted more than 75 clinical trials across four continents, evaluating the safety, tolerability and immunogenicity of numerous study products, delivery methods and regimens. During the conducting of all HVTN studies, participant data and specimens are collected at multiple time points to evaluate immunogenicity and generate data across several cellular and humoral research platforms. In addition, extra samples are collected and stored for use in other studies potentially related to vaccinology, immunology and HIV. The HVTN maintains comprehensive metadata for all specimens, and has collected more than one million pages of case report form data from study participants to date. The HVTN is committed to making the specimens and data collected in HVTN studies available to investigators around the world to foster the development of diverse, hypothesis-driven research projects to advance HIV vaccine science. This session will provide a brief overview of the types of specimens, data and resources available to investigators to formulate research hypotheses, as well as steps to approach collaborating with the HVTN. This overview will be followed by a showcase of several, ongoing research projects initiated by investigators in collaboration with the HVTN and utilizing HVTN specimens and/or data.

Chairs:

James Kublin (Fred Hutchinson Cancer Research Center, United States)
Ashley Clayton

Download Program (PDF)

Satellites
08:30 - 11:30

Dresden & Stuttgart

SA08, Catalyzing Translational Research to Advance HIV Vaccine and Immune-based Cure Research in Africa: Cross-cutting Translational Research and Capacity Strengthening in Africa

Hosted by: IAVI and University of KwaZulu Natal

This satellite will showcase early and mid-level career African scientists supported by a 15-year IAVI-led USAID-funded capacity program and from the SANTHE consortium, part of the DELTAS Africa Initiative, an independent funding scheme of the African Academy of Sciences' (AAS's) Alliance for Accelerating Excellence in Science in Africa (AESAs). This satellite workshop will aim to provide evidence of the impact that these investments have created in translational biomedical research in Africa. This session will also host a moderated panel discussion by African investigators to share personal career pathways, experiences and perspectives on how research capacity and research outputs could be further strengthened and improved on the continent.

Chairs:

Daniel Ochiel (IAVI, Kenya)
Thumbi Ndung'u (University of KwaZulu-Natal, South Africa)

Satellites
08:30 - 11:30

Estrasburgo

SA10, Immunological Mechanisms of Inducing HIV Immunity in Infants

Hosted by: Division of AIDS, NIAID, NIH

The session aims to better understand: (i) how the unique tolerogenic nature of the human fetal immune system and developing immune-tolerance in infants provide a unique setting for B-cell maturation pathways and development of early and broad immunity to HIV; and (ii) how to prioritize HIV candidate vaccines and target populations for assessment of infant HIV immunization.

Chairs:

Mary Marovich (Division of AIDS, NIAID, NIH, United States)
Sallie Permar (Duke University Medical Center)
Anjali Singh (Division of AIDS, NIAID, NIH)

Satellites
08:30 - 11:30

Burdeos

SA12, Voices in the Long-acting PrEP Movement: Fostering Dialog Between End-users and Product Developers During the Product Development Process

Hosted by: RTI International, Desmond Tutu HIV Research Foundation, AVAC and IAVI

This satellite session aims to demonstrate and discuss strategies to foster open and iterative dialog between end-users and product developers of long-acting HIV prevention products. The objective of hosting this satellite is directly in line with the theme of this year's HIVR4P Conference, From Research to Impact. Satellite presenters, those working both in product development and those interfacing with target populations of young women in Southern Africa, aim to achieve synergistic solutions for the development of long-acting HIV PrEP products that are safe, effective, acceptable and appropriate for their target end-users, a goal that will ultimately achieve the greatest public health impact.

Chairs:

Linda-Gail Bekker (Desmond Tutu HIV Centre, University of Cape Town, South Africa)

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Satellites
08:30 - 11:30

Marsella

SA14, GPP@10 -- Setting New Standards for Clinical Trial Engagement Globally

Hosted by: AVAC, Amsterdam Institute for Global Health and Infectious Diseases

Through presentations and moderated discussions, the session will articulate evolved the Good Participatory Practices (GPP) after 10 years of implementation, debate challenges and questions around GPP, and explore consensus on GPP as a standard in clinical trials.

Chairs:

Stacey Hannah (AVAC, United States)

Catherine Hankins (Amsterdam Institute for Global Health and Development, Netherlands)

Satellites
12:00 - 15:00

Bristol

SA17, Love, Power and PrEP: Addressing Relationship Dynamics and Intimate Partner Violence to Promote Successful HIV Prevention for Women and Girls

Hosted by: FHI 360, RTI International, Population Council and Wits Reproductive Health and HIV Institute

To successfully empower women and girls to protect themselves against HIV, researchers, policy makers, funders, advocates and programmers need a nuanced understanding of how relationship dynamics affect HIV prevention and interventions that jointly address these issues. This satellite session will summarize the state of the evidence on the effect of gender inequality on the HIV risk of women and girls and their use of HIV prevention methods, including pre-exposure prophylaxis (PrEP). New evidence will be presented from adolescent girls, young women, key populations and male partners in Kenya, Ghana and Tanzania on their HIV prevention needs and preferences, including their views on PrEP and how intimate partner violence (IPV) could affect PrEP access and use. A panel of experts will present new evidence from clinic- and community-based interventions (CHARISMA, EMPOWER and Project SOAR) implemented in South Africa and Tanzania, jointly addressing relationship dynamics, IPV, HIV prevention and PrEP.

Chairs:

Kawango Agot (Impact Research & Development Organization, Kenya)

Jared Baeten (University of Washington, United States)

Satellites
12:00 - 15:00

Oxford

SA19, Whose Desire? Whose Choice? A Debate on the Future of HIV Prevention

Hosted by: AVAC and IRMA

Lively, moderated discussion and debate featuring speakers from funding agencies, research networks and sites, product developers and the advocacy community. Panelists will unpack the evolving HIV prevention research priorities and product development agendas, and share thoughts on what is necessary to develop prevention products that people desire and what we mean by giving people "choices."

Chairs:

Mitchell Warren (AVAC, United States)

Helen Rees (Wits Reproductive Health and HIV Institute, South Africa)

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Satellites
12:00 - 15:00

Dresden & Stuttgart

SA09, Fc-mediated Antibody Functions Impacting HIV Prevention

Hosted by: NIH/NIAID/Division of AIDS

Fc-mediated antibody functions, including antibody-dependent cell cytotoxicity (ADCC), are potential mechanisms that the immune system can resource to prevent the establishment of HIV infection by eliminating HIV and/or HIV-infected cells. This session will bring together investigators to review NHP and clinical data on Fc-mediated antibody functions in the context of HIV/SIV infection and vaccine design, to discuss the biological relevance and limitations of different assays and to provide insights into immunogen design strategies to maximize the induction of antibodies with Fc-mediated functions that could impact HIV infection and persistence.

Chairs:

Christiane Moog (INSERM U1109, FMTS, Université de Strasbourg, France)
Stephen Kent (University of Melbourne, Australia)

Satellites
12:00 - 15:00

Estrasburgo

SA11, Accelerating a Labor of Love: Time to Transform HIV Prevention for Pregnant and Breastfeeding Women

Hosted by: Jhpiego, MTN, PHASES, AVAC

A growing body evidence supports the need to expand biomedical HIV prevention options during pregnancy and breastfeeding, periods known to have increased risk for HIV acquisition for both women and their infants. While the large majority of biomedical HIV prevention trials have excluded pregnant and breastfeeding women, this trend is starting to change. HIV pre-exposure prophylaxis (PrEP) programs are starting to serve pregnant and breastfeeding women, and the conversation around equitable access for these populations is evolving. The proposed session would highlight the growing body of evidence, action, advocacy, and ethics around increasing access for pregnant and breastfeeding women to safe and effective biomedical HIV prevention options.

Chairs:

Sharon Hillier (University of Pittsburgh, United States)
Kelly Curran

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Satellites
12:00 - 15:00

Burdeos

SA13, It Only Hurts a Little: Long-acting Injectables for HIV Prevention and Treatment

Hosted by: Center for HIV Identification, Prevention and Treatment Services at the University of California, Los Angeles

Ongoing clinical trials of long-acting injectable antiretroviral medications are being studied currently as both HIV prevention and maintenance of virologic suppression in HIV treatment. If safe and effective, long-acting agents have the potential to significantly impact the HIV epidemic by eliminating the requirement for daily oral dosing of antiretrovirals. This may have significant benefits for individuals living with or at risk for HIV, particularly among those who also have co-morbidities that complicate daily routinization of medication dosing, such as mental health and substance use disorders. Such individuals also commonly face structural issues, including housing instability and food insecurity, which can interfere with their capacity for daily oral medication adherence and persistence. With the first regulatory approvals of long-acting injectable antiretrovirals imminent, this interactive satellite session aims to facilitate efforts to mobilize, prepare and plan for culturally responsive, equitable and sustainable scale-up of long-acting injectable prevention and treatment agents for key populations in high-, middle- and low-income countries. The session will engage multidisciplinary stakeholders, including academic experts, policy researchers and civic society members, in a dialogue to articulate the challenges for implementation and uptake and, in particular, how acceptability and/or barriers may differ from those applicable to daily oral tablet formulations. The session will convene two moderated panels to discuss clinical, behavioral, policy and community considerations associated with the implementation of long-acting injectable antiretrovirals for prevention and treatment in the context of different international resource settings and key populations (for example, MSM, transgender women, pregnant and parenting cisgender women, youth).

Chairs:

Steven Shoptaw (UCLA Medical Center, Santa Monica, United States)
Raphael Landovitz (UCLA Center for Clinical AIDS Research & Education, United States)

Satellites
12:00 - 15:00

Marsella

SA15, Human Centric Vaccine Discovery

Hosted by: EAVI2020

This session will highlight the importance of discovery-phase clinical vaccine trials.

Chairs:

Robin Shattock (Imperial College, United Kingdom)

Opening Plenary
16:00 - 18:00

Auditorium

PL01, Planning for Success (and the Challenges Ahead)

Plenary 1 opens HIVR4P 2018 with a broad statement of our goals, a look at the major challenges facing the field as we convene and a tribute to some of the researchers and advocates who are taking it forward and keeping us focused.

Chairs:

Jose Alcamí (Instituto de Salud Carlos III, Spain)
Susan Buchbinder (San Francisco Department of Public Health, United States)
Mike Chirenje (University of Zimbabwe, Zimbabwe)
Georgia Tomaras (Duke University, United States)

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Welcome to HIVR4P 2018	16:00 - 16:10
Desmond Tutu Award for HIV Prevention and Human Rights	16:10 - 16:17
HIV Vaccines: Where Are We and What Next? <u>Linda-Gail Bekker</u> (South Africa)	16:17 - 16:47
Novel Trial Designs for a Complex Environment <u>Sheena McCormack</u> (United Kingdom)	16:47 - 17:17
Ending the HIV/AIDS Pandemic: The Critical Role of HIV Prevention Science <u>Anthony S. Fauci</u> (United States)	17:17 - 17:47
The Omololu Falobi Award for Excellence in HIV Prevention Research Community Advocacy	17:47 - 17:55
HIVR4P 2018 Scholars	17:55 - 18:00

Welcome Reception
18:00 - 20:00

Foyer

Welcome Reception

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Tuesday, 23 October 2018

Plenary
08:30 - 10:00

Auditorium

PL02, What Happens First: Understanding Susceptibility, Transmission and Early Infection

Plenary 2 dives deep into some of the most fundamental and challenging questions about the earliest moments of infection, when HIV enters the complex mucosal microenvironment, and how untangling the mysteries of susceptibility and infection can lead to smarter, more targeted prevention approaches.

Chairs:

Felipe Garcia (IDIBAPS, Spain)

Julie McElrath (Fred Hutchinson Cancer Research Center, United States)

Visualizing HIV Transmission and Prevention

08:30 - 09:00

Thomas J. Hope (United States)

First Responders: What Early Infection Teaches About Prevention and Functional Cure Strategies

09:00 - 09:30

Thumbi Ndung'u (South Africa)

Untangling Hormonal Impacts on the Vaginal Microbiome and HIV Acquisition Risk

09:30 - 10:00

Sharon Achilles (United States)

Oral
10:30 - 12:00

Londres

OA01, Location, Location, Location: Mucosal Mediators of Risk

Chairs:

Lindi Masson (University of Cape Town, South Africa)

Doug Kwon (Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital and Harvard Medical School, United States)

Oral
10:30 - 12:00

Bristol

OA02, Immunity in Human Vaccine Trials

Chairs:

Gabriella Scarlatti (San Raffaele Scientific Institute, Italy)

Laura Richert (Vaccine Research Institute/VRI, France)

DNA-prime Induces Higher Magnitude Humoral Responses Than ALVAC-prime in HIV Vaccine Regimens With the Same Protein Boost

11:15 - 11:30

Zoe Moodie, Craig Innes, Mina Hosseinipour, Sarita Naidoo, Linda-Gail Bekker, Fatima Laher, Nicole Grunenberg, Philipp Mann, Chenchen Yu, M. Juliana McElrath, Georgia Tomaras, Nicole Yates, Lynn Morris, Nono Mkhize, David Montefiori, Mary Allen, James Kublin, Glenda Gray, Peter B. Gilbert, Lawrence Corey (United States)

Download Program (PDF)

Vaccine-induced Gene Signature Correlates With Protection Against Acquisition in Three Independent Vaccine Efficacy Trials Including RV144

11:30 - 11:45

Biju Issac, Philip Ehrenberg, Michael Eller, Galit Alter, Rafick Sekaly, Merlin Robb, Robert Gramzinski, Maria Pau, Hanneke Schuitemaker, Dan Barouch, Nelson Michael, [Rasmi Thomas](#) (United States)

Primary Analysis of TRAVERSE: A Phase 1/2a Study to Assess Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost HIV Vaccine Regimens

11:45 - 12:00

[Daniel J. Stieh](#), Katleen Callewaert, Michal Sarnecki, Jenny Hendriks, Steven Nijs, Zelda Euler, Hanneke Schuitemaker, Georgia D. Tomaras, James G. Kublin, Lawrence Corey, M. Julie McElrath, Julie Ake, Merlin L. Robb, Galit Alter, Dan H. Barouch, Maria G. Pau, Frank L. Tomaka (Netherlands)

Oral
10:30 - 12:00

Oxford

OA03, Structure and Maturation of bNAbs

Chairs:

Alejandro Balazs (Ragon Institute of MGH, MIT and Harvard, United States)

Human Antibody Repertoire Informatics-guided Design of Candidate Immunogens to Prime V2-apex Broadly Neutralizing Antibody Responses

11:45 - 12:00

Oral
10:30 - 12:00

Marsella, Burdeos & Estrasburgo

OA04, Entry Into the PrEP Continuum

Chairs:

Rupa Patel (Washington University in St. Louis, United States)

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Meet the Experts Lunch
12:00 - 13:00

Toulouse & Lyon

ME01, Meet the Experts Lunch

Daily meet the experts lunches provide early-career investigators and community advocates with valuable opportunities for informal, in-depth exchange with experts representing a cross-section of research issues, implementation challenges, and HIV-affected communities.

Chairs:

Linda-Gail Bekker (Desmond Tutu HIV Centre, University of Cape Town, South Africa)
Marta Boffito (Chelsea and Westminster NHS Trust, United Kingdom)
Charles Dobard (Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, Laboratory Branch, United States)
Irene Mukui (National AIDS & STI Control Program, Kenya)
Emily Bass (AVAC, United States)
Jeffrey Murray (FDA, United States)
Deborah Donnell (Fred Hutchinson Cancer Research Center, United States)
Luciana Kamel (Fiocruz, Brazil)
Gertrude Nanyonjo (UVRI-IAVI HIV Vaccine Program, Uganda)
Manish Sagar (Boston University, United States)
Andrew Harman (The Westmead Institute, University of Sydney, Australia)
Alexandra Schuetz (MHRP Thailand, Thailand)
Zhiwei Chen (The University of Hong Kong AIDS Institute, China)
Lynn Morris (National Institute for Communicable Diseases of the NHLS, South Africa)
Eloisa Yuste (Instituto de Salud Carlos III, Spain)
Kevin Saunders (Duke Human Vaccine Institute, United States)
Thomas Hope (Northwestern University, United States)
Sharon Achilles (University of Pittsburgh, United States)
Sheena McCormack (MRC Clinical Trials Unit at UCL, United Kingdom)
William Schief (The Scripps Research Institute and IAVI, United States)
Thumbi Ndung'u (University of KwaZulu-Natal, South Africa)
Eric Arts (University of Western Ontario, Canada)
Walid Heneine (CDC, United States)

Meet the Experts Lunch

12:00 - 13:00

Oral
13:00 - 14:30

Londres

OA05, If I Choose, Will I Use? Products, People and Preferences

Chairs:

Mary Aikenhead (Bill and Melinda Gates Foundation, United States)
Mina Hosseinipour (University of North Carolina at Chapel Hill, Malawi)

UChoose: An Adolescent Study of HIV Prevention Choice in Cape Town, South Africa

14:15 - 14:30

Oral
13:00 - 14:30

Bristol

OA06, Mucosal Models of Prevention

Chairs:

Carolina Herrera (Imperial College London, United Kingdom)
Thandi Onami (Bill & Melinda Gates Foundation, United States)

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Oral
13:00 - 14:30

Oxford

OA07, Understanding Protection Against HIV From the T Cell Perspective

Chairs:

Marcus Altfeld (Heinrich Pette Institute, Germany)
Richard Koup (Vaccine Research Center, United States)

Oral
13:00 - 14:30

Marsella, Burdeos & Estrasburgo

OA08, bNAbs for Prevention

Chairs:

Boris Juelg (Ragon Institute of MGH, MIT and Harvard, United States)
Alexandra Trkola (University of Zurich, Switzerland)

Symposium
15:00 - 16:30

Londres

SY01, We Want bNAbs: Passively Infused and Induced by Vaccines

This session will look at state-of-the-art passive infusion designs, including optimal combinations to achieve maximum breadth, coverage, potency and durability. In addition, multiple vaccine concepts designed to induce bNAbs will be presented, from the stage of basic concept up to the clinical trials pipeline.

Chairs:

Quentin Sattentau (Sir William Dunn School of Pathology, United Kingdom)
Marina Caskey (The Rockefeller University, United States)

Engineered Tandem Bispecific Neutralising Antibody for HIV-1 Prevention and Immunotherapy <u>Zhiwei Chen</u> (China)	15:00 - 15:18
Antibody Mediated Protection (AMP): Where Are We? Which Antibodies to Use and How Will We Know If It's Working? <u>Lynn Morris</u> (South Africa)	15:18 - 15:36
Generation of Immunogens Based on HIV-1 Envelopes From Patients With Broadly Neutralizing Responses Within the First 6 Months of Infection Carolina Beltran-Pavez, Nuria Gonzalez, Amanda Fabra-Garcia, Alberto Merino-Mansilla, Alex Olvera, Jose Maria Miro, Christian Brander, Jose Alcami, <u>Eloisa Yuste</u> , Victor Sanchez-Merino (Spain)	15:36 - 15:54
HIV-1 Vaccine Design for the Elicitation of V3-glycan Broadly Neutralizing Antibodies <u>Kevin Saunders</u> (United States)	15:54 - 16:12
Progress in Germline-targeting Vaccine Design for HIV <u>William Schief</u> (United States)	16:12 - 16:30

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Symposium
15:00 - 16:30

Bristol

SY02, Early Invaders: Establishment of HIV Infection

This session addresses virus-host interaction at the mucosal border where transmission occurs and where cells involved in early immune responses are both viral targets and defense mechanisms.

Chairs:

Penny Moore (University of the Witwatersrand, South Africa)
Cecilia Cabrera (IrsiCaixa AIDS Research Institute, Spain)

Selection of Transmitted Founder Viruses During Sexual HIV-1 Acquisition	15:00 - 15:22
<u>Manish Sagar</u> (United States)	
Identification of a New HIV Transmitting Target Cell in Human Genital Tissue	15:22 - 15:44
<u>Andrew Harman</u> (Australia)	
Characteristics Leading to HIV Trapping in the Female Genital Tract and Systemic Primary Infection During Transmission	15:44 - 16:06
<u>Eric Arts</u> (Canada)	
Mucosal Immunology in the Context of Acute HIV Infection and HIV Remission Studies	16:06 - 16:28
<u>Alexandra Schuetz</u> (Thailand)	

Symposium
15:00 - 16:30

Oxford

SY03, Beyond Placebo: Designing and Implementing Next Generation HIV Prevention Trials

This session will explore challenges in designing and conducting the next generation of HIV prevention trials. Topics discussed will include regulatory perspectives, novel trial designs, ethical considerations in provision of standard of prevention, and active community engagement in the design and successful implementation of complex trials in an era of proven HIV prevention tools (including voluntary medical male circumcision and oral PrEP).

Chairs:

Catherine Hankins (Amsterdam Institute for Global Health and Development, Netherlands)
Peter Godfrey-Faussett (UNAIDS, Switzerland)

Regulatory Perspectives for Streamlining HIV Prevention Trials	15:00 - 15:22
<u>Jeffrey Murray</u> (United States)	
Novel Trial Design in the Era of Successful HIV Prevention Interventions	15:22 - 15:44
<u>Deborah Donnell</u> (United States)	
Ethics in the Provision of Standard of Prevention Among Participants in Low- and Middle-income Countries	15:44 - 16:06
Strengthen Community Expertise on the Important Aspects of Clinical Trial Design	16:06 - 16:28
<u>Luciana Kamel</u> (Brazil)	
<u>Luciana Kamel</u> (Brazil)	

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Symposium
15:00 - 16:30

Marsella, Burdeos & Estrasburgo

SY04, ARVs for Prevention: Extrapolating from Data to Clinical Practice

Data on mechanisms for PrEP efficacy are somewhat limited, and interpretation varies in creating policy about timing of starting and stopping PrEP for protection. This session will explore the PK, PD and clinical trials, and discuss implications of what is currently known for developing policy on PrEP.

Chairs:

Lara Coelho (Instituto de Pesquisa Clínica Evandro Chagas, Fundação Oswaldo Cruz, Brazil)
Clemensia Nakabiito (MUJHU Research Collaboration, Uganda)

Pharmacokinetics of PrEP Agents: Where Do Drugs Go? How Long Do They Last?	15:00 - 15:22
<u>Marta Boffito</u> (United Kingdom)	
Lessons Learned from Pre-clinical Animal Models on Pharmacokinetics and Pharmacodynamics of ARVs for PrEP	15:22 - 15:44
<u>Charles Dobard</u> (United States)	
Understanding PrEP Effectiveness in Different Populations in the Context of Public Health Programs	15:44 - 16:06
<u>Irene Mukui</u> (Kenya)	
The PrEP Paradigm for Prevention, Advocacy and Implementation in sub-Saharan Africa: Strong Starts, Short Cuts, and the Use (and Abuse?) of Data	16:06 - 16:28
<u>Emily Bass</u> (United States)	

Poster Discussion
16:45 - 17:30

Londres

PD01, Revealing Targets for Prevention and Cure

Chairs:

Damian Purcell (Doherty Institute, University of Melbourne, Australia)

Trogocytosis of Viral Immune Complexes in the Context of HIV-1 Infection	17:12 - 17:21
---	----------------------

Poster Discussion
16:45 - 17:30

Bristol

PD02, MEN-ding the Gaps

Chairs:

Kennedy Mupeli (Center for youth of hope (CEYOH), Botswana)
Michelle Rodolph (WHO, Switzerland)

Reaching Men and Under Tested Populations in South Africa Using the STAR Wits RHI HIV Self-screening Test Kits Distribution Models	17:21 - 17:30
Joel Francis, <u>Mohammed Majam</u> , Jane Phiri, Vincent Zishiri, Angela Tembo, Mimi Nombeu, Mpumelelo Sibanda, Francois Venter (South Africa)	

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Poster Discussion
16:45 - 17:30

Oxford

PD03, Insights From Vaccines for Improved Breadth, Potency and Durability

Chairs:

Anatoli Kamali (International AIDS Vaccine Initiative, Kenya, Kenya)

Increase in Env-specific Binding Antibody and CD4+ T Cell-responses After Month 30 Boost of gp120/MF59 Delivered Alone or With ALVAC-HIV

17:21 - 17:30

Kristen Cohen, Mookho Malahleha, Fatima Laher, Linda-Gail Bekker, Kathryn Mngadi, Brodie Daniels, Craig Innes, Zoe Moodie, Nicole Grunenberg, Mary Allen, Shannon Grant, Chenchu Yu, Sanjay Phogat, Carlos DiazGranados, Marguerite Koutsoukos, Georgia Tomaras, James Kublin, Lawrence Corey, Glenda Gray, M. Juliana McElrath (United States)

Poster Discussion
16:45 - 17:30

Marsella, Burdeos & Estrasburgo

PD04, PrEP: Doing It Right at Delivery

Chairs:

Joshua Kimani (University of Nairobi, Kenya)

Predictors of PrEP Drug Adherence Among Female Sex Workers in Mysore and Mandya, India: Insights From a Community-led PrEP Demonstration Project

16:54 - 17:03

Sushena Rezapaul, Lisa Lazarus, Raviprakash K.N., Partha Halder, Venugopal M.S., Manjula Ramaiah, Rob Lorway, Marissa Becker, Salaheddin Mahmud, Stephen Moses (Canada)

Poster Discussion
16:45 - 17:30

Dresden & Stuttgart

PD05, Microbiome: When Microorganisms and the Immune System Meet

Chairs:

Sinaye Ngcapu (Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa)
Sergio Serrano-Villar (Hospital Universitario Ramón y Cajal, Spain)

Human Gut Microbiota Are Associated With HIV-reactive Immunoglobulin at Baseline and Following HIV Vaccination

17:21 - 17:30

Jacob Cram, Andrew Fiore-Gartland, Sujatha Srinivasan, Shelly Karuna, Giuseppe Pantaleo, David Fredricks, James Kublin (United States)

Download Program (PDF)

Wednesday, 24 October 2018

Plenary
08:30 - 10:00

Auditorium

PL03, The Future is Now: Next Steps in Developing New Prevention Options

Plenary 3 answers the question, "What's new in prevention?" with a look at systemic and topical agents in development, new approaches to vaccines and new methods of delivery that could transform the future of HIV prevention.

Chairs:

Ian McGowan (University of Pittsburgh, United States)
Julia del Amo (Instituto de Salud Carlos III, Spain)

Beyond TDF/FTC: The Future of Systemic Pre-exposure Prophylaxis	08:30 - 09:00
Raphael Landovitz (United States)	
On-demand Topical Agents for HIV Pre-exposure Prophylaxis	09:00 - 09:30
Craig Hendrix (United States)	
Vaccine Design 2.0: The Pipeline Novel HIV-1 Envelope Proteins to Induce Neutralizing Antibodies	09:30 - 10:00
Rogier Sanders (Netherlands)	

Oral
10:30 - 12:00

Londres

OA09, Translating Immunity From Pre-clinical Animal Models to Humans

Chairs:

Roger LeGrand (CEA, France)
Mariangela Cavarelli (CEA, France)

A Meta-analysis to Evaluate the Relationship Between Serum Antibody Neutralizing Titer and Protection Against SHIV Challenge in Nonhuman Primates	11:45 - 12:00
Ying Huang , Amarendra Pegu, Yunda Huang, Matthias Pauthner, Lindsay Carpp, Mario Roederer, Lawrence Corey, Peter Gilbert, Dennis Burton, John Mascola (United States)	

Oral
10:30 - 12:00

Bristol

OA10, Key to the Response: Populations, Partners and Prevention

Chairs:

Kenneth H. Mayer (Fenway Health, United States)
Valdilea Veloso (Fundação Oswaldo Cruz, Brazil)

Download Program (PDF)

HIV Incidence Among Men Who Have Sex With Men and Transgender Women in Sub-Saharan Africa: Findings From the Multi-country HPTN 075 Cohort Study

11:15 - 11:30

Theo G.M. Sandfort, Xu Guo, Erica L. Hamilton, Ying Q. Chen, Vanessa Cummings, Charlotte Gaydos, Wairimu Chege, Michael Stirratt, Blessings Madiwati, Arthur Ogendo, Ravindre Panchia, Doeriyah Reynolds, Susan H. Eshleman (United States)

Oral
10:30 - 12:00

Oxford

OA11, Novel Vaccine Strategies

Chairs:

Susan Barnett (Bill and Melinda Gates Foundation, United States)
Yoann Aldon (Imperial College London, United Kingdom)

Immune Responses to PENNVAX-GP (R) HIV DNA Vaccine Plus IL-12 Are Equivalent or Superior When Delivered by Intradermal vs. Intramuscular Electroporation

11:45 - 12:00

Srilatha Edupuganti, Stephen De Rosa, Yunda Huang, Xao Han, Mengshu Shao, Marnie Elizaga, Edith Swann, Laura Polakowski, Spyro Kalams, Mike Keefer, Janine Maenza, Georgia Tomaras, Megan Wise, Matthew Morrow, Amir Khan, Jean Boyer, Michael Pensiero, Niranjana Sardesai, Mark Bagarazzi, David Weiner (United States)

Symposium
10:30 - 12:00

Marsella, Burdeos & Estrasburgo

SY11, ARVs for Prevention in Women of Childbearing Age

Chairs:

Elizabeth Bukusi (KEMRI, Kenya)
Gita Ramjee (South African Medical Research Council, South Africa)

No Woman Left Behind: An Ethical Framework for Prevention Studies in Reproductive Age Women

10:30 - 10:52

Annie Lysterly (University of North Carolina, United States)

Efavirenz and Dolutegravir: A Tale of Two ARVs

10:52 - 11:14

Studying Periconception Outcomes in Women on ARVs in Brazil

11:14 - 11:36

Adele Benzaken (Brazil)

Striking a Balance

11:36 - 11:58

Sharon Hillier (University of Pittsburgh, United States)

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Meet the Experts Lunch
12:00 - 13:00

Toulouse & Lyon

ME02, Meet the Experts Lunch

Daily meet the experts lunches provide early-career investigators and community advocates with valuable opportunities for informal, in-depth exchange with experts representing a cross-section of research issues, implementation challenges, and HIV-affected communities.

Chairs:

Hasina Subedar (Department of Health, South Africa)
Alex Coutinho (Partners in Health, Rwanda)
Anthony Cunningham (The Westmead Institute, The University of Sydney, Australia)
Mary Carrington (Frederick National Laboratory for Cancer Research, United States)
Zaza Ndhlovu (University of KwaZulu Natal, South Africa)
Sarit Golub (Hunter College, United States)
Wendy Burgers (Institute of Infectious Disease and Molecular Medicine, UCT, South Africa)
Tony Kelleher (Kirby Institute, UNSW Sydney, Australia)
Rama Amara (Emory University, United States)
Raphael Landovitz (UCLA Center for Clinical AIDS Research & Education, United States)
Craig Hendrix (Johns Hopkins University, United States)
Rogier Sanders (Amsterdam Medical Center, Cornell University, Netherlands)
Renee Heffron (University of Washington, United States)
Nneka Nwokolo (Chelsea & Westminster Hospital, United Kingdom)
R. Keith Reeves (Beth Israel Harvard, United States)
Maximilian Muenchhoff (Pettenkofer-Institute, Germany)
Maria del Rosario Leon (Impacta Salud y Educacion, Peru)
Martha Brady (PATH, United States)
Annie Lysterly (University of North Carolina, United States)
Adele Benzaken (Ministry of Health, Brazil, Brazil)
Sharon Hillier (University of Pittsburgh, United States)

Meet the Experts Lunch

12:00 - 13:00

Oral
13:00 - 14:30

Londres

OA12, Contraception and HIV Risk: Still Between a Rock and a Hard Place

Chairs:

Charles Morrison (FHI 360, United States)

Safety and Pharmacokinetics of Dapivirine and Levonorgestrel Vaginal Rings for Multipurpose Prevention of HIV and Pregnancy

13:15 - 13:30

Sharon L. Achilles, Craig W. Hendrix, Samuel M. Poloyac, Craig J. Hoesley, Melissa Peda, Holly Gundacker, Barbara S. Mensch, Mark A. Marzinke, Brid Devlin, Annalene M. Nel, Jeanna M. Piper, Sherri Johnson, Beatrice A. Chen (United States)

Oral
13:00 - 14:30

Bristol

OA13, Virus Control: Therapeutic Interventions

Chairs:

Moses Nsubuga (Stigmaless Uganda, Uganda)
Mariano Esteban (Centro Nacional De Biotecnología, Spain)

Download Program (PDF)

Tissue Viral Seeding Drives SHIV Pathogenesis in Infant Macaques and Is Reduced by Early bNAb Therapy

14:15 - 14:30

Ann Hessel, Mariya Shapiro, Delphine Malherbe, James Kobie, Amarendra Pegu, Xuejun Chen, Don Siess, Benjamin Bimber, Tracy Cheever, Shilpi Pandey, Rebecca Lewinsohn, Gabriela Webb, Jason Reed, Christoph Kahl, Byung Park, Anne Lewis, Jonah Sacha, John Mascola, Nancy Haigwood (United States)

Oral
13:00 - 14:30

Oxford

OA14, Antibody Functions Beyond Neutralization

Chairs:

Christiane Moog (INSERM U1109, FMTS, Université de Strasbourg, France)
Cynthia Derdeyn (Emory University, United States)

Tight Control of SHIV_{BaL} in Rhesus Macaques Immunized With gp160 DNA + gp120 Proteins (Clades E and B) Correlates With V2p Antibodies

14:15 - 14:30

Oral
13:00 - 14:30

Marsella, Burdeos & Estrasburgo

OA15, New ARVs for Prevention

Chairs:

Anton Pozniak (Chelsea and Westminster Hospital, United Kingdom)
Juan Berenguer (Infectious Diseases at Hospital General Gregorio Marañón, Spain)

Tail-phase Safety, Tolerability and Pharmacokinetics of Long-acting Injectable Cabotegravir in HIV-uninfected Individuals: HPTN 077 Final Results

14:15 - 14:30

Raphael J. Landovitz, Sue Li, Joseph J. Eron, Beatriz Grinsztejn, Halima Dawood, Albert Y. Liu, Many Magnus, Mina C. Hosseinipour, Ravindre Panchia, Leslie Cottle, Paul Richardson, Mark A. Marzinke, Susan H. Eshleman, Ryan Kofron, Adeola Adeyeye, David Burns, Alex R. Rinehart, David Margolis, Marybeth McCauley, Craig W. Hendrix (United States)

Symposium
15:00 - 16:30

Londres

SY05, Close Encounters of the Third Kind: Innate and Adaptive Immune Responses in HIV Dissemination

This session will review host responses to HIV/SIV infection within mucosal and lymphoid tissues in humans and nonhuman primates. Topics will include the role of molecular pathways implicated in natural immune control, early host response, novel mucosal innate lymphocyte subsets, and relevant findings from acute HIV infection studies.)

Chairs:

Hendrik Streeck (Institute for HIV Research, Germany)
Guido Silvestri (Emory University, United States)

Download Program (PDF)

Interfering with Interferons: How HIV Subverts the Interferon System to Facilitate Sexual HIV Transmission	15:00 - 15:22
<u>Anthony Cunningham</u> , Najla Nasr, Orion Tong, Caroline Royle, Andrew Harman (Australia)	
Fixed Characteristics of HLA Class I Alleles That Impact HIV Disease	15:22 - 15:44
<u>Mary Carrington</u> (United States)	
HIV Persistence and the Immune Microenvironment in Lymph Nodes Following Initiation of cART During Hyperacute HIV-1 Infection	15:44 - 16:06
<u>Zaza Ndhlovu</u> , Omolara Baiyegunhi, Funsho Ogunshola, Krista Dong, Thumbi Ndung'u, Bruce Walker (South Africa)	
The First Line Against HIV/SIV: Innate Immune Effectors at the Virus-Mucosae Interface	16:06 - 16:28
<u>R. Keith Reeves</u> (United States)	

Roundtable
15:00 - 16:30

Bristol

RT01, Accelerating Product Introduction for Impact

Millions of new HIV infections occur yearly despite availability of novel and effective HIV prevention products. This session will explore best practices for introduction of prevention products, and discuss successes and challenges using lessons learnt from completed demonstration projects. Best practices from sexual and reproductive health technologies and experiences from non-HIV vaccines will be used as examples of implementation planning for product introduction.

Chairs:

Nyaradzo Mgodi (University of Zimbabwe Collaborative Research Program, Zimbabwe)
Mitchell Warren (AVAC, United States)

Preparing for Successful Implementation of Prevention Strategies	15:00 - 15:10
<u>Hasina Subedar</u> (South Africa)	
Learning From the Past: Planning for Future Success in Implementing Biomedical HIV Prevention Products	15:10 - 15:20
<u>Alex Coutinho</u> (Rwanda)	
Successes and Shortcomings in Introducing Sexual and Reproductive Health Technologies: Insights From End-users, Providers and Policy Makers	15:20 - 15:30
<u>Martha Brady</u> (United States)	
Learning from History: Roll-out of Non-HIV Vaccines	15:30 - 15:40
Mark Feinberg (International AIDS Vaccine Initiative, United States)	
Introduction of New Health Technologies in HIV Prevention and Treatment Trials: Best Practices of Community Engagements and Communication in Peru	15:40 - 15:50
<u>Maria Del Rosario Leon</u> , Javier Lama, Pedro Gonzales (Peru)	
Panel Discussion	15:50 - 16:30

Download Program (PDF)

Symposium
15:00 - 16:30

Oxford

SY06, Let's Talk T Cells!

There is an urgent need to revisit approaches to elicit cell-mediated immunity for both vaccine prevention and cure strategies. The session will cover the latest and greatest candidates in pre-clinical and clinical development, as well as address the need to strike the right balance of T cell immunity.

Chairs:

Paul Goepfert (University of Alabama at Birmingham, United States)
Julia G. Prado (AIDS Research Institute Irsicaixa, Spain)

T Cell Responses in HIV-infected Children: Potential for Prevention or Cure?	15:00 - 15:18
<u>Maximilian Muenchhoff</u> , Philip Goulder (Germany)	
T Cells in Vaccine Trials	15:18 - 15:36
<u>Wendy A. Burgers</u> (South Africa)	
What Defines an Effective T-cell Response to HIV?	15:36 - 15:54
<u>Christian Brander</u> (Spain)	
Role of Tfh in Protective Immunity	15:54 - 16:12
<u>Anthony D. Kelleher</u> , Mee Ling Munier, Yin Xu, Brad Milner, Solange Obeid, Florence Bascombe, Annett Howe, John Zaunders (Australia)	
Vaccine-induced Th1-biased CD4 T Cell Responses: Too Much can be Bad	16:12 - 16:30
<u>Rama Amara</u> (United States)	

Symposium
15:00 - 16:30

Marsella, Burdeos & Estrasburgo

SY07, Optimizing PrEP Delivery for PrEP Users

This session will discuss the next phase of PrEP implementation – removing barriers to uptake and persistence of PrEP. The talks will focus on integrating PrEP with family planning. They will include: discussion of MPTs; discussion of new PrEP delivery strategies, such as pharmacy- or telemedicine-based delivery; exploration of “positive frame” methods of describing PrEP to help individuals determine whether they might benefit from PrEP; and discussion of new technologies for increasing uptake and persistence of PrEP.

Chairs:

Will Nutland (PrEPster, United Kingdom)
Omar Sued (Fundacion Huesped, Argentina)

Integrating PrEP and Reproductive Health Services and Preparing for MPT Delivery	15:00 - 15:22
<u>Renee Heffron</u> (United States)	
New Delivery Approaches: Improving PrEP Uptake and Persistence	15:22 - 15:44
<u>Nneka Nwokolo</u> (United Kingdom)	
PrEP Messaging: Taking “Risk” Out of the Pitch	15:44 - 16:06
<u>Sarit Golub</u> (United States)	
Mobilizing Communities Through Innovations to Improve PrEP Uptake	16:06 - 16:28
<u>Nittaya Phanuphak</u> (Thailand)	

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Poster Discussion
16:45 - 17:30

Londres

PD06, Mechanisms of Natural Control

Chairs:

Marianne Mureithi (University of Nairobi, Kenya)
Yves Levy (INSERM, France)

Single-cell Cloning of HIV-specific Natural Killer Cells in Humans

17:03 - 17:12

Olivier Lucar, Paul Goepfert, Stephanie Jost, Roger Keith Reeves (United States)

Poster Discussion
16:45 - 17:30

Bristol

PD07, Beyond Acronyms: Understanding Young Women's Dreams, Realities and Perceptions

Chairs:

Definate Nhamo (Pangaea Zimbabwe AIDS Trust (PZAT), Zimbabwe)

Poster Discussion
16:45 - 17:30

Oxford

PD08, Trials and Tribulations in Roll Out

Chairs:

Stacey Hannah (AVAC, United States)
Morenike Ukpog (Institute of Public Health, Obafemi Awolowo University; New HIV Vaccine and Microbicide Advocacy Society, Nigeria)

Poster Discussion
16:45 - 17:30

Marsella, Burdeos & Estrasburgo

PD09, Long-Acting Prevention Agents in Experimental Models

Chairs:

Stephanie Barrett (Merck & Co., Inc., United States)

Poster Discussion
16:45 - 17:30

Dresden & Stuttgart

PD10, Roadmaps for bNAb Elicitation

Chairs:

Amelia Escolano (The Rockefeller University, United States)

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Dual Maturation Pathways from the Unmutated Common Ancestor of HIV-1 Envelope Broadly Neutralizing Antibodies Overcome Glycan Barriers

17:21 - 17:30

Mattia Bonsignori, Eric Scott, Kevin Wiehe, David Easterhoff, S. Munir Alam, Kwan-Ki Hwang, David C. Montefiori, Rory Henderson, Xuejun Chen, M. Gordon Joyce, Peter D. Kwong, Mark Connors, John R. Mascola, Andrew T. McGuire, Leonidas Stamatatos, Max Medina-Ramirez, Rogier W. Sanders, Kevin O. Saunders, Thomas B. Kepler, Barton F. Haynes (United States)

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Thursday, 25 October 2018

Oral
08:30 - 10:00

Londres

OA16, Tickling the Germline

Chairs:

Marit van Gils (Amsterdam AMC, University of Amsterdam, Netherlands)
Ian Wilson (The Scripps Research Institute, United States)

Oral
08:30 - 10:00

Bristol

OA17, Factors Influencing Viral Transmission and Spread

Chairs:

Nabila Seddiki (Inserm U955, Team 16, France)
Jason Brenchley (Niaid, United States)

Treatment of Schistosoma mansoni Infection in Ugandan Women Reduces HIV Entry Into Cervical CD4 T Cells and Induces Type I Interferon Pathways

08:45 - 09:00

Sergey Yegorov, Vineet R. Joag, Ronald M. Galiwango, Sara V. Good, Juliet Mpendo, Egbert Tannich, Andrea K. Boggild, Noah Kiwanuka, Bernard S. Bagaya, Rupert Kaul (Canada)

Oral
08:30 - 10:00

Oxford

OA18, Opinion 360: Meaningful Engagement From Research to Roll Out

Chairs:

Manju Chatani-Gada (AVAC, United States)
Kundai Chinyenze (International AIDS Vaccine Initiative, Kenya)

Oral
08:30 - 10:00

Marsella, Burdeos & Estrasburgo

OA19, Stay With Me: Retention on PrEP

Chairs:

Ferran Pujol Roca (Projecte dels NOMS-Hispanosida, Spain)

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Oral
10:30 - 12:00

Londres

OA20, Into the Future With Delivery Technologies

Chairs:

Charles Lacey (University of York, United Kingdom)
Zeda Rosenberg (IPM, United States)

Development of an End-user Informed Tenofovir Alafenamide (TAF) Implant for Long-acting (LA)-HIV Pre-exposure Prophylaxis (PrEP)

10:45 - 11:00

Gregory J. Gatto, Rhonda M. Brand, Natalie Girouard, Linying A. Li, Leah Johnson, Mark A. Marzinke, Emily Krogstad, Aaron Siegel, Emily Helms, Zach Demkovich, Ellen Luecke, Ariane van der Straten (United States)

Oral
10:30 - 12:00

Bristol

OA21, Linking Arms in Defense: Innate, Cellular and Humoral

Chairs:

Francesca Chiodi (Karolinska Institutet, Sweden)
Montserrat Plana (Institut d'Investigacions Biomèdiques August Pi i Sunyer, Spain)

The Impact of Vaccination on SIV Evolution Following Break-through Infection

11:45 - 12:00

Kathryn Foulds, Will Fischer, Mitzi Donaldson, Shing-Fen Kao, Amy Ransier, Jianfei Hu, Brandon Keele, Daniel Douek, Mario Roederer (United States)

Oral
10:30 - 12:00

Oxford

OA22, Antibody Virus Tango

Chairs:

Katie Doores (King's College London, United Kingdom)
Feng Gao (Duke University, United States)

Oral
10:30 - 12:00

Marsella, Burdeos & Estrasburgo

OA23, Great Expectations: The Impact of PrEP

Chairs:

Ume Abbas (Baylor College of Medicine, United States)

Decreased HIV Incidence Among PrEP Users Compared to Non-users in a Boston Community Health Center, 2012-2017

11:15 - 11:30

Kenneth Hugh Mayer, Douglas Krakower, Christina Grasso, Kenneth Levine, Victoria Powell, Juwan Campbell, Julia Marcus (United States)

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Meet the Experts Lunch
12:00 - 13:00

Toulouse & Lyon

ME03, Meet the Experts Lunch

Chairs:

Jessica Haberer (Massachusetts General Hospital/Harvard Medical School, United States)
Ariane van der Straten (RTI International, United States)
Wanjiru Mukoma (LVCT Health, Kenya)
Ram Prasad (Final Mile, United States)
Robert H. Remien (NY State Psychiatric Institute and Columbia University, United States)
Lena Serghides (University Health Network and University of Toronto, Canada)
Bruce Richman (U=U, United States)
Guido Ferrari (Duke University Medical Center, United States)
Michael Gale (University of Washington, United States)
Heather Jaspan (University of Cape Town/ Seattle Children's Research Institute, South Africa)
Colleen Kelley (Emory University School of Medicine, United States)
Cara Wilson (University of Colorado, United States)
Diane Havlir (University of California at San Francisco, United States)
Maureen Luba (Centre for the Development of People (CEDEP), Malawi)
Michael Meulbroek (BCN Checkpoint, Spain)
John Mascola (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, United States)
John Brooks (Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, United States)
Monica Vaccari (United States)
Genoveffa Franchini (National Cancer Institute, United States)
Connie Celum (University of Washington, United States)
Sudhir Kasturi (Emory University, United States)
Nelly Mugo (Kenya Medical Research Institute (KEMRI), Kenya)

Meet the Experts Lunch

12:00 - 13:00

Symposium
13:00 - 14:30

Londres

SY08, Translating Vaccine Concepts to the Clinic: What We Need to Know

Based on current vaccine concepts, we will do a deep dive into immune mechanisms of protection. Using appropriate animal models, we will evaluate the crosstalk between adaptive and innate immunity, and signatures of protection. Finally, we will examine the role of susceptibility and how to modulate responses.

Chairs:

Sandhya Vasan (Military HIV Research Program, Henry M. Jackson Foundation, Thailand)
Nathalie Dereuddre-Bosquet (CEA, France)

Insights Into NK Cell Suppressor Activity in Secondary Lymphoid Organs Revealed by Animal Models

13:00 - 13:18

Michaela Muller-Trutwin (France)

Influence of Vaccine Composition on Envelope Recognition by HIV-1 Vaccine-induced Antibody-dependent Cellular-mediated Cytotoxic Responses

13:18 - 13:36

Guido Ferrari, Leigh Fisher, Giuseppe Pantaleo, Gavin Churchyard, Glenda Gray, Susan Buchbinder, Srilatha Edupuganti, Linda-Gail Bekker, Lindsey Baden, Paul Goepfert, Scott Hammer, David Montefiori, Georgia Tomaras, Peter Gilbert, Julie McElrath, Larry Corey (United States)

Download Program (PDF)

Antibody Interference and Durable Monocyte Innate Memory Decrease SIV_{mac251} Acquisition Risk Following Immunization with the DNA/ALVAC/gp120 Regimen	13:36 - 13:54
<u>Genoveffa Franchini</u> (United States)	
Protective Gene Expression Signature of the RhCMV/SIV Vaccine: Lessons for Human Studies	13:54 - 14:12
Connor Driscoll, Richard Green, Fredrik Barrenas, Jean Chang, Elise Smith, Lynn Law, Scott Hansen, Louis Picker, <u>Michael Gale</u> (United States)	
Modulating Durability of HIV-1 Env Specific Humoral Immunity With 3M-052, a TLR7/8 Targeted Adjuvant	14:12 - 14:30
<u>Sudhir Pai Kasturi</u> , Ata Ur Rasheed, Parin Patel, Colin Havenar-Daughton, Shane Crotty, Mark Tomai, Christopher Fox, Steven Reed, Rafi Ahmed, Bali Pulendran (United States)	

Symposium
13:00 - 14:30

Bristol

SY09, Choosing to Use: What People Want from HIV Prevention

HIV prevention products currently in use were introduced after successful clinical trials for efficacy with little consideration of user preference. Results from completed efficacy trials consistently show evidence of low product use among adolescent and young women. This session will explore strategies for adherence support, risk perception, social marketing and end-user engagement strategies during product development.

Chairs:

Andrew Mujugira (Infectious Diseases Institute, Uganda)
Sinead Delany-Moretlwe (University of the Witwatersrand, South Africa)

Defining and Supporting Prevention Adherence	13:00 - 13:22
<u>Jessica Haberer</u> (United States)	
Risk Perception and End-users' Perspective: Insights From Research of MPTs and HIV Prevention Products	13:22 - 13:44
<u>Ariane van der Straten</u> (United States)	
Creating Demand for HIV Prevention Products, Programs and Services	13:44 - 14:06
<u>Wanjiru Mukoma</u> (Kenya)	
Preference and Habits: How Do Users Decide and How Do We Find Out?	14:06 - 14:28
<u>Ram Prasad</u> (United States)	

Download Program (PDF)

Symposium
13:00 - 14:30

Oxford

SY10, Mucosal Environment: Barriers and Facilitators of Transmission

This session will review how mucosal environments influence the likelihood that HIV transmission occurs following viral exposure. This includes a review of mucosal factors such as microbes and host responses that influence sexual transmission, and immunological mechanisms that dictate the integrity of the mucosal barrier and availability of HIV target cells.

Chairs:

William Kilembe (Zambia Emory HIV Research Project, Zambia)
Lyle McKinnon (University of Manitoba, Canada)

Microbiota and HIV Transmission	13:00 - 13:22
<u>Heather Jaspan</u> (United States)	
High Prevalence of Bacterial STIs in HIV-positive Persons: Transmission Implications & Potential Interventions	13:22 - 13:44
<u>Connie Celum</u> (United States)	
The Rectal Mucosa in At-risk Men who Have Sex With Men: HIV Target Cells and the Inflammatory Response to Condomless Receptive Anal Intercourse	13:44 - 14:06
<u>Colleen Kelley</u> (United States)	
How Do Different Components of the Mucosal Microenvironment Interact to Influence HIV Susceptibility?	14:06 - 14:28
Cara Wilson (University of Colorado, United States)	

Roundtable
13:00 - 14:30

Marsella, Burdeos & Estrasburgo

RT02, Getting to U: Undetectable = Untransmittable

People living with HIV who are durably virally suppressed are not able to transmit sexually. This roundtable will explore the psychological and behavioral components in deciding to start and stay on treatment, evaluate population impact of viral suppression, explore whether U=U holds for breastfeeding, describe what is known about clinical cohorts of persons being treated and their level of viral suppression, and discuss how to get the word out about U=U within communities.

Chairs:

Judith Auerbach (University of California, San Francisco, United States)
Ntando Yola (Desmond Tutu HIV Foundation, South Africa)

Starting and Staying on ARVs	13:00 - 13:10
<u>Robert H. Remien</u> (United States)	
What are the population level studies teaching us about U=U?	13:10 - 13:20
Nelly Mugo (Kenya Medical Research Institute (KEMRI), Kenya)	
What Does U=U Mean for Breastfeeding?	13:20 - 13:30
<u>Lena Serghides</u> (Canada)	
How Do You Know You're "U"?	13:30 - 13:40
<u>John T. Brooks</u> (United States)	

Download Program (PDF)

U=U: Unpacking the Message and the Movement	13:40 - 13:50
<u>Bruce Richman</u> (United States)	
Panel Discussion	13:50 - 14:30

Closing Plenary
15:00 - 16:30

Auditorium

PL04, Putting It Together: Strategies to End the Epidemic

Plenary 4 looks ahead to the potential impact of implementing multiple prevention strategies, and challenges researchers and advocates from every community and prevention field to pool our knowledge, share our experiences and move forward together to help end the epidemic.

Chairs:

Jose Alcamí (Instituto de Salud Carlos III, Spain)
Susan Buchbinder (San Francisco Department of Public Health, United States)
Georgia Tomaras (Duke University, United States)
Mike Chirenje (University of Zimbabwe, Zimbabwe)

Combination prevention: What will it take to make it work?	15:00 - 15:20
Diane Havlir (University of California at San Francisco, United States)	
Implementing a Multi-disciplinary Prevention Revolution	15:20 - 15:35
<u>Maureen Luba</u> (United States)	
The Impact of Prevention Strategies on HIV Incidence in a Community Center	15:35 - 15:50
<u>Michael Meulbroek</u> (Spain)	
A Path Forward for HIV Vaccines	15:50 - 16:10
<u>John Mascola</u> (United States)	
Panel Discussion with Closing Plenary Speakers	16:10 - 16:25
Closing Remarks and Handover to 2020	16:25 - 16:30